NCT07154823Recruiting
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 550 (estimated)
- First submitted
- 19 Aug 2025
- Start date
- 27 Jan 2026
- Primary completion date
- 30 Nov 2034
- Lead sponsor
- Tempus AI
- NCT number
- NCT07154823
What you commit to
- Study type: Observational
- Planned participants: 550
- From 27 Jan 2026 to the primary completion date, 30 Nov 2034
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- All Cohorts Inclusion Criteria:
- Willing and able to participate in the research and provide biospecimens
- Willing and able to provide informed consent
- Cohort 001 Inclusion:
- Have documented diagnosis of AML according to the World Health Organization (WHO) classification
- Secondary AML is allowed
- Cohort 002 Inclusion:
- Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)
- Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)
- 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation
- 002B (Newly Diagnosed, High Risk): Intended for first line treatment
- 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)
- 002C (Relapsed / Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment
- 002D (Transformed FL): Pathologically confirmed transformation
- All Cohorts Exclusion Criteria:
- 1\. Not willing or able to adhere with the study procedures
- Cohort 001:
- 1\. Have received any prior therapy intended for standard of care (SoC) treatment of AML
- Cohort 002:
- 002A: Received prior treatment for follicular lymphoma
- 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN
- 002A: Resected patients with NED
- 002B: Intended for active observation
- 002B: Received prior treatment for follicular lymphoma
Age in the registry: 0 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Center for Cancer and Blood Disorders Coordinator of this site? Confirm its status | Bethesda | United States | Recruiting |
| Novant Health Weisiger Cancer Institute Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
| University of Cincinnati Coordinator of this site? Confirm its status | Cincinnati | United States | Recruiting |
| OhioHealth Research Institute Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
| Sanford Fargo Coordinator of this site? Confirm its status | Fargo | United States | Recruiting |
| University of Iowa Hospital and Clinics Coordinator of this site? Confirm its status | Iowa City | United States | Recruiting |
| Taylor Cancer Research Center Coordinator of this site? Confirm its status | Maumee | United States | Recruiting |
| Cancer Care Specialists of Reno Coordinator of this site? Confirm its status | Reno | United States | Recruiting |
| University of Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
| Sanford Sioux Falls Coordinator of this site? Confirm its status | Sioux Falls | United States | Recruiting |
| Avera Cancer Institue Coordinator of this site? Confirm its status | Sioux Falls | United States | Recruiting |
| Washington University in St. Louis Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| Cancer Care Associates of York Coordinator of this site? Confirm its status | York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.